

Product Datasheet

Cevipabulin

Catalog No. **BP-02475** · CAS **849550-05-6** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Microtubule/Tubulin	Research area Cancer
--------------------------------------	--------------------------------

Molecular formula **C₁₈H₁₈ClF₅N₆O**

Molecular weight **464.8200**

STRUCTURE



DESCRIPTION

Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC₅₀ of 18-40 nM for cytotoxicity in human tumor cell line .

BIOLOGICAL ACTIVITY

In Vitro

Cevipabulin (0-50 nM, 72 hours) shows good activity (between 18 and 40 nM IC₅₀ values) on cell lines from ovarian, breast, prostate, and cervical tumors.

Flow cytometry experiments reveal that, Cevipabulin (TTI-237) at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block.

n Vivo

Cevipabulin (TTI-2370)(5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles, in mice) is active by i.v. and p.o. administration against human tumor xenografts, showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1].Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300.

[2]. Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64(4):681-9.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.